Table 1 Characteristics of the samples in the pilot study (n = 12)

Control

Sample 1

37

Male

-

-

-

Sample 2

38

Male

-

-

-

Sample 3

28

Female

-

-

-

Sample 4

25

Female

-

-

-

Sample 5

34

Female

-

-

-

Sensitivity

Sensitivity_1

59

Male

13%

NK/T lymphoblastic lymphoma, stage IV group B, IPI 3 score

P-GELOX (gemcitabine 1.4 mg, d1, 8; Pemendon 3750 d1; Oxalipol 150 mg d1)

Sensitivity_2

59

Male

-

Extranodal NK/T cell lymphoma, nasal type, Stage IV Group A, IPI 2 score

P-GELOX (gemcitabine 1.8 g, d1, 8; Pemendon 3750 d1; Oxalipol 180 mg d1)

Sensitivity_3

26

Male

0.5%

Primary cutaneous peripheral T-cell lymphoma

P-Gemox(Pemaspartase 3750 u d1, gemcitabine 1.6 g d1, d8, oxaliplatin 150 mg d1)

Sensitivity_4

43

Female

2%

Primary cutaneous peripheral T-cell lymphoma

GDP + etoposide (gemcitabine 1.3 g, d1, 8; Dexamethasone 40 mg d1-4; Cisplatin 100 mg d1; Etoposide 80 mg d1-4)

Experimental

Experimental_1

47

Male

-

NK/T cell lymphoma stage II Group A, IPI 1 Score

P-Gemox(Pemaspartase 3750 u d1, gemcitabine 1.6 g d1, d8, oxaliplatin 150 mg d1)

Experimental_2

62

Male

-

Peripheral T cell lymphoma stage III Group B, IPI 1 Score

GDP (Gemcitabine 1.6 g, d1, 8; Dexamethasone 40 mg d1-4; Cisplatin 120 mg d1)

Experimental_3

51

Male

25%

T-lymphoblastic lymphoma, stage III Group B, IPI 1 Score

Sidanidine + GDP (Sidanidine 30 mg, d1, 4, 8, 11; Dexamethasone 40 mg, d1-4; Gemcitabine 1.6 g, d1, 1.2 g, d8; Cisplatin 120 mg, d1)

Sensitivity

Sensitivity_5

54

Male

-

T-lymphoblastic lymphoma stage I, low risk group. (No IPI score)

COP tumor reduction and BFM-90 treatment were performed 4 times

Sensitivity_6

70

Male

-

Extranodal NK/T cell lymphoma, nasal type, Stage IIB, IPI2 score, Low risk group

P-GELOX (gemcitabine 1.8 g, d1, 8; Pemendon 3750 d1; Oxalipol 180 mg d1) and radiotherapy

Sensitivity_7

25

Female

-

Acute leukemia

MA scheme treatment were performed

Experimental

Experimental_4

16

Male

-

Stage III T-lymphoblastic lymphoma (mediastinum, neck, supraclavicular lymph nodes)

VDLP scheme, CAM scheme were performed twice, M scheme treatment were performed 3 times

Experimental_5

55

Male

-

Peripheral T cell lymphoma, non-specific type, stage IVB, IPI 4 score, high risk group

CHOP scheme were performed twice, ESHAP scheme, GDP and sidarbenamide scheme treatment

Experimental_6

60

Female

-

T-lymphoblastic lymphoma stage III, low risk group. (No IPI score)

VDLP + CAM scheme, M scheme were performed 4 times and VDLP scheme treatment